total vegfr 2 Search Results


human total vegfr2 kdr duoset ic elisa kit  (R&D Systems)
92
R&D Systems human total vegfr2 kdr duoset ic elisa kit
Fig. 3. Cellular localization and level of <t>VEGFR2</t> in an AD brain. A) Double-labelling of VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells and the tunica media of larger vessels, and also in neurons and GFAP-positive astrocytes. Bar = 100 m. B) This image shows more clearly the combination or brown (VEGFR2) and purple (GFAP) reaction product within astrocytes. Bar = 50 m. C) Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-localization of these antigens within microglia. A capillary shows a membranous pattern of VEGFR2 immunolabeling. Bar = 50 m. D) VEGFR2 protein level (measured by ELISA) did not differ significantly between control and AD homogenates (p = 0.42). Each point represents a single brain. Median ± interquartile range are also displayed.
Human Total Vegfr2 Kdr Duoset Ic Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/total+vegfr+2/Human+Total+VEGFR2%2FKDR+DuoSet+IC+ELISA/pm29226875-76-6-15
Average 92 stars, based on 1 article reviews
human total vegfr2 kdr duoset ic elisa kit - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
anti phosphorylated extracellular signal regulated kinase1 2 perk  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc anti phosphorylated extracellular signal regulated kinase1 2 perk
Fig. 3. Cellular localization and level of <t>VEGFR2</t> in an AD brain. A) Double-labelling of VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells and the tunica media of larger vessels, and also in neurons and GFAP-positive astrocytes. Bar = 100 m. B) This image shows more clearly the combination or brown (VEGFR2) and purple (GFAP) reaction product within astrocytes. Bar = 50 m. C) Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-localization of these antigens within microglia. A capillary shows a membranous pattern of VEGFR2 immunolabeling. Bar = 50 m. D) VEGFR2 protein level (measured by ELISA) did not differ significantly between control and AD homogenates (p = 0.42). Each point represents a single brain. Median ± interquartile range are also displayed.
Anti Phosphorylated Extracellular Signal Regulated Kinase1 2 Perk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/total+vegfr+2/PathScan+Total+VEGFR-2+Sandwich+ELISA+Kit/pmc12461152-270-9-17
Average 93 stars, based on 1 article reviews
anti phosphorylated extracellular signal regulated kinase1 2 perk - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
total vegfr-2 kit  (Merck KGaA)
90
Merck KGaA total vegfr-2 kit
Fig. 3. Cellular localization and level of <t>VEGFR2</t> in an AD brain. A) Double-labelling of VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells and the tunica media of larger vessels, and also in neurons and GFAP-positive astrocytes. Bar = 100 m. B) This image shows more clearly the combination or brown (VEGFR2) and purple (GFAP) reaction product within astrocytes. Bar = 50 m. C) Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-localization of these antigens within microglia. A capillary shows a membranous pattern of VEGFR2 immunolabeling. Bar = 50 m. D) VEGFR2 protein level (measured by ELISA) did not differ significantly between control and AD homogenates (p = 0.42). Each point represents a single brain. Median ± interquartile range are also displayed.
Total Vegfr 2 Kit, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/total+vegfr+2/total+vegfr+2+kit/pm27484635-48-19-3
Average 90 stars, based on 1 article reviews
total vegfr-2 kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human phospho-vegfr2 (tyr996) and total vegfr2 elisa  (RayBiotech)
N/A
RayBio® Human Phospho-VEGFR2 (Tyr996) and Total VEGFR2 ELISA Kit. This assay semi-quantitatively measures VEGFR2 phosphorylated at Tyrosine-996 as well as total VEGFR2 in cell lysate samples.
   Buy from Supplier
pathscan total vegfr-2 sandwich elisa antibody pair  (Cell Signaling Technology Inc)
N/A
Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are
   Buy from Supplier
alphalisa surefire ultra total vegfr-2 control lysate  (PerkinElmer)
N/A
This control lysate is intended for use with the AlphaLISA SureFire Ultra total VEGFR-2 assay kit, or for use as a control for those running orthogonal or secondary assays along with the SureFire assay. To
   Buy from Supplier
total vegfr-2 alphalisa surefire ultra high volume detection kit, 100 assay points  (PerkinElmer)
N/A
The AlphaLISA® SureFire® Ultra™ Total VEGFR-2 assay is a sandwich immunoassay for quantitative detection of VEGF receptor 2 (both phosphorylated and non-phosphorylated) in cellular lysates using Alpha Technology. This assay is intended to be used
   Buy from Supplier

Image Search Results


Fig. 3. Cellular localization and level of VEGFR2 in an AD brain. A) Double-labelling of VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells and the tunica media of larger vessels, and also in neurons and GFAP-positive astrocytes. Bar = 100 m. B) This image shows more clearly the combination or brown (VEGFR2) and purple (GFAP) reaction product within astrocytes. Bar = 50 m. C) Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-localization of these antigens within microglia. A capillary shows a membranous pattern of VEGFR2 immunolabeling. Bar = 50 m. D) VEGFR2 protein level (measured by ELISA) did not differ significantly between control and AD homogenates (p = 0.42). Each point represents a single brain. Median ± interquartile range are also displayed.

Journal: Journal of Alzheimer's disease : JAD

Article Title: VEGFR1 and VEGFR2 in Alzheimer's Disease.

doi: 10.3233/JAD-170745

Figure Lengend Snippet: Fig. 3. Cellular localization and level of VEGFR2 in an AD brain. A) Double-labelling of VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells and the tunica media of larger vessels, and also in neurons and GFAP-positive astrocytes. Bar = 100 m. B) This image shows more clearly the combination or brown (VEGFR2) and purple (GFAP) reaction product within astrocytes. Bar = 50 m. C) Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-localization of these antigens within microglia. A capillary shows a membranous pattern of VEGFR2 immunolabeling. Bar = 50 m. D) VEGFR2 protein level (measured by ELISA) did not differ significantly between control and AD homogenates (p = 0.42). Each point represents a single brain. Median ± interquartile range are also displayed.

Article Snippet: VEGFR2 protein level was measured using Human Total VEGFR2 (KDR) Duoset IC ELISA kit (DYC1780, R&D Systems) according to the manufacturer’s guidelines.

Techniques: Immunolabeling, Enzyme-linked Immunosorbent Assay, Control

Fig. 4. VEGF in relation to vWF, VEGFR1, and VEGFR2. A) Scatterplots showing vWF level in the homogenates of parietal cortex. The horizontal lines indicate the median ± interquartile values. The level of vWF did not differ significantly between control and AD brains (Mann-Whitney test, p = 0.143). C: n = 36, AD: n = 50. B) VEGF level was higher in AD than control brains although this did not reach significance (Mann-Whitney test, p = 0.069) C: n = 31, AD: n = 45. C) No correlation between VEGF and vWF in control (p = 0.525, r = 0.119, n = 31) or AD (p = 0.437, r = –0.119, n = 45) parietal cortex. Each point represents one brain. ∗p < 0.05.

Journal: Journal of Alzheimer's disease : JAD

Article Title: VEGFR1 and VEGFR2 in Alzheimer's Disease.

doi: 10.3233/JAD-170745

Figure Lengend Snippet: Fig. 4. VEGF in relation to vWF, VEGFR1, and VEGFR2. A) Scatterplots showing vWF level in the homogenates of parietal cortex. The horizontal lines indicate the median ± interquartile values. The level of vWF did not differ significantly between control and AD brains (Mann-Whitney test, p = 0.143). C: n = 36, AD: n = 50. B) VEGF level was higher in AD than control brains although this did not reach significance (Mann-Whitney test, p = 0.069) C: n = 31, AD: n = 45. C) No correlation between VEGF and vWF in control (p = 0.525, r = 0.119, n = 31) or AD (p = 0.437, r = –0.119, n = 45) parietal cortex. Each point represents one brain. ∗p < 0.05.

Article Snippet: VEGFR2 protein level was measured using Human Total VEGFR2 (KDR) Duoset IC ELISA kit (DYC1780, R&D Systems) according to the manufacturer’s guidelines.

Techniques: Control, MANN-WHITNEY

Fig. 5. Hypothesized relevance of present findings in the context of vascular homeostasis and hypoperfusion of the parietal cortex in AD. Cerebral amyloid angiopathy (CAA), decreased choliner- gic innervation of intracerebral blood vessels [10, 11], reduced NO production [12–15] and an increase in vasoconstrictors EDN1 [16,19]andAngII,throughupregulationofangiotensin-converting enzyme (ACE)-1 and downregulation of ACE-2 [17, 18]) may all contribute to reduced cerebral blood flow. Reduced tissue oxygena- tion leads to increased VEGF [3, 29–32] that is not accompanied by an increase in endothelial von Willebrand factor (vWF) level and microvessel density [3]. Reduction in VEGFR1 is probably a physiological response to reduced oxygenation but an increase in thesolubleformofthereceptorprotein(sVEGFR1)maycontribute to impaired angiogenesis. VEGFR2 level remains unchanged. Arrows denote an increase (↑) or decrease (↓) in protein in AD compared to control. Horizontal double arrow (↔) indicates no change in AD compared to controls.

Journal: Journal of Alzheimer's disease : JAD

Article Title: VEGFR1 and VEGFR2 in Alzheimer's Disease.

doi: 10.3233/JAD-170745

Figure Lengend Snippet: Fig. 5. Hypothesized relevance of present findings in the context of vascular homeostasis and hypoperfusion of the parietal cortex in AD. Cerebral amyloid angiopathy (CAA), decreased choliner- gic innervation of intracerebral blood vessels [10, 11], reduced NO production [12–15] and an increase in vasoconstrictors EDN1 [16,19]andAngII,throughupregulationofangiotensin-converting enzyme (ACE)-1 and downregulation of ACE-2 [17, 18]) may all contribute to reduced cerebral blood flow. Reduced tissue oxygena- tion leads to increased VEGF [3, 29–32] that is not accompanied by an increase in endothelial von Willebrand factor (vWF) level and microvessel density [3]. Reduction in VEGFR1 is probably a physiological response to reduced oxygenation but an increase in thesolubleformofthereceptorprotein(sVEGFR1)maycontribute to impaired angiogenesis. VEGFR2 level remains unchanged. Arrows denote an increase (↑) or decrease (↓) in protein in AD compared to control. Horizontal double arrow (↔) indicates no change in AD compared to controls.

Article Snippet: VEGFR2 protein level was measured using Human Total VEGFR2 (KDR) Duoset IC ELISA kit (DYC1780, R&D Systems) according to the manufacturer’s guidelines.

Techniques: Control